CompletedPhase 1NCT04522986

An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Rohto Pharmaceutical Co., Ltd.
Principal Investigator
Yuji Fujino, MD
Osaka University Hospital
Intervention
Mesenchymal stem cell(biological)
Enrollment
6 target
Eligibility
20 years · All sexes
Timeline
20202021

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04522986 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials